

**October 24, 2024****Contents**

Clinical Profile Documentation .....	2
Problem Groups .....	2
Additions .....	2
Problems.....	3
Additions.....	3
Lab Analytes & Panels .....	3
Analyte Additions.....	3
Panel Additions .....	3
Medications.....	4
Additions.....	4
Updates .....	4
Regimen Library.....	5
Additions.....	5
Updates .....	6
Renames .....	7
Removals .....	7
Billing & HCPCS Codes .....	7
Updates .....	7
Appendix A.....	8
Problem & Code Summary.....	8
Additions.....	9

# Clinical Profile Documentation

## Problem Groups

### Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

**HER2 by IHC** was updated for **Biliary Tract Cancers, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Head and Neck Cancer, Melanoma, Lung Cancer, Non-small Cell (NSCLC), Ovarian and Primary Peritoneal Cancer, Pancreatic Cancer, Rectal Cancer, and Uterine Cancer** with the following documentation points:

- 3+
- 2+
- 1+
- 0
- Unknown

**HER2 by ISH** was updated for **Breast Cancer** with the following documentation points:

- Positive
- Negative
- Unknown

**HER2 by ISH or NGS** is now available for **Biliary Tract Cancers, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer, and Uterine Cancer** with the following documentation points:

- Positive
- Negative
- Unknown

**HER2 status** was updated for **Breast Cancer** with the following documentation points:

- Positive: IHC 3+ or IHC 2+/ISH-positive
- Low: IHC 1+ or IHC 2+/ISH-negative
- Negative: IHC 0
- Unknown

# Problems

## Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes may be displayed to present the surrounding nodes.

Please see APPENDIX A for a complete summary of changes.

# Lab Analytes & Panels

## Analyte Additions

- CYP2C cluster geno
- CYP2C cluster pheno
- CYP2C9 genotype
- CYP2C9 phenotype
- CYP4F2 genotype
- CYP4F2 phenotype
- HBV genotype + drug resistance
- LDL calculation comment
- Total cells counted, CSF
- VKORC1 phenotype
- West Nile virus IgM, CSF

## Panel Additions

- HBV genotype + drug resistance panel
- Jak2 mutation, quantitative w/reflex to Exons 12-15 panel
- Myeloma, FISH panel, tissue panel
- Genetic result summary
  - Genetic interpretation
  - Genetic result table
  - Genetic reason for referral
  - Genetic specimen
  - Genetic source
  - Genetic tissue ID
  - Genetic method
  - Genetic disclaimer
  - Genetic released by

## Medications

### Additions

- CB-010 invest IV
- IFx-Hu2.0 invest Intralesional
- INCB057643 invest Oral
- Olvimulogene Nanivacirepvec (Olvi-Vec) invest IV

### Updates

Medication	Update
AZD5305 invest Oral	New <b>Alias</b> : Saruparib invest (AZD5305 invest Oral)
Tecentriq Hybreza (atezolizumab-hyaluronidase-tqjs Subcutaneous 1,875 mg-30,000 unit/15 mL)	New <b>SIG</b> : 1,875 mg subcutaneously every 3 weeks; administer over 7 minutes; administer in the thigh over approximately 7 minutes.
VET3-TFI invest Intratumoral	New <b>Units</b> : <ul style="list-style-type: none"> <li>• x 10e7 pfu</li> <li>• x 10e8 pfu</li> <li>• x 10e9 pfu</li> </ul> Deactivated <b>Units</b> : <ul style="list-style-type: none"> <li>• e7 pfu</li> <li>• e8 pfu</li> <li>• e9 pfu</li> </ul>
VET3-TGI invest IV	New <b>Units</b> : <ul style="list-style-type: none"> <li>• x 10e7 pfu</li> <li>• x 10e8 pfu</li> <li>• x 10e9 pfu</li> </ul> Deactivated <b>Units</b> : <ul style="list-style-type: none"> <li>• e7 pfu</li> <li>• e8 pfu</li> <li>• e9 pfu</li> </ul>

# Regimen Library

## Additions

Regimen Name	Diagnosis
Atezolizumab SQ Q21D	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ Q21D (Adjuvant NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Abraxane D1,8,15 + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Bevacizumab Q21D	Hepatocellular Carcinoma (HCC)
Atezolizumab SQ + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab SQ + Bevacizumab Maintenance)	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Carboplatin + Etoposide D1-3 Q21D	Lung Cancer, Non-small Cell (NSCLC)
Influenza Vaccines 2024-2025	All Problems
Isatuximab-irfc + Carfilzomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Isatuximab-irfc IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q42D (Part 2 of 2: Isatuximab-irfc IV + Lenalidomide + Dexamethasone Continuation Q28D, non-transplant candidates)	Multiple Myeloma (MM)
Pembrolizumab + Pemetrexed + Carboplatin Q21D (Mesothelioma)	Malignant Mesothelioma; Malignant Pleural Mesothelioma
Pembrolizumab + Pemetrexed + Cisplatin Q21D (Mesothelioma)	Malignant Mesothelioma; Malignant Pleural Mesothelioma
Tislelizumab-jsgr Q21D	Esophageal Cancer (Parent); Hepatocellular Carcinoma (HCC)
Vemurafenib + Cobimetinib Q28D fb Vemurafenib + Cobimetinib (Q28D) + Atezolizumab SQ (Q21D) Q84D (Part 1 of 2)	Melanoma, Skin

Regimen Name	Diagnosis
Vemurafenib + Cobimetinib Q28D fb Vemurafenib + Cobimetinib (Q28D) + Atezolizumab SQ (Q21D) Q84D (Part 2 of 2)	Melanoma, Skin
Venetoclax + Azacitidine D1-7 Q28D (AML)	Leukemia, Acute Myeloid (AML)
Venetoclax + Decitabine D1-5 Q28D (AML)	Leukemia, Acute Myeloid (AML)
Zoledronic acid (Zometa) Q28D (Hypercalcemia of Malignancy)	All Malignancies

## Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Hemolytic Uremic Syndrome
- Leukemia, Acute Myeloid (AML)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma
- Myasthenia Gravis
- Myelodysplastic Syndrome (MDS)
- Myelofibrosis
- Myeloproliferative Disorder
- Ovarian and Primary Peritoneal Cancer
- Paroxysmal Nocturnal Hemoglobinuria
- Polycythemia Vera
- Thalassemia
- Uterine Cancer (Parent)
- Waldenstrom's Macroglobulinemia

## Renames

Previous Name	New Name
Isatuximab-irfc IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q42D	Isatuximab-irfc IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q42D (Part 1 of 2: Induction)
Venetoclax + Azacitidine D1-7 Q28D	Venetoclax + Azacitidine D1-7 Q28D (Myelofibrosis)
Venetoclax + Decitabine D1-5 Q28D	Venetoclax + Decitabine D1-5 Q28D (MDS, Myelofibrosis)

## Removals

Regimen Name	Diagnosis
Atezolizumab + Abraxane D1,8 Q14D fb Atezolizumab + Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense	Breast Cancer
Atezolizumab Q21D (Adjuvant Breast)	Breast Cancer
Voxelotor Q30D	Anemia, Sickle Cell

## Billing & HCPCS Codes

### Updates

Medication	HCPCS Codes
Anthrax immune globulin (human) IV	J1599 per 60 units
Guselkumab IV	J1628 per 1 mg
Guselkumab Subcutaneous Pen Injector	J1628 per 1 mg
Influenza virus vaccine (PF) IM Tri-Split 65 yrs & older (High-Dose)	90662 per: 180 mcg 0.5 mL 1 EA
Ocrelizumab-hyaluronidase-ocsq Subcutaneous	J3590 per 23 mL
Palonosetron IV	J2469 per 0.025 mg

Medication	HCPCS Codes
Pentamidine IV	J3490 per 300 mg

## Appendix A

### Problem & Code Summary

For the retired and replacement problems listed below, please follow steps 1-9 to update the patient records in the **iKM Clinical Profile**, problems area to support regimen management:

1. Locate the replacement problem in the second column
2. Chart the replacement problem in iKM Clinical Profile, Problems
3. Go to the patients flow sheet
4. Select the regimen
5. Select Edit regimen properties
6. Select drop-down for Associated problem, select the new replacement problem
7. Select Line of Therapy drop-down and select
8. Save
9. Document problem information (staging, biomarkers, etc.) in new problem

Retired Problem	Replacement Problem
Benign carcinoid tumor of left kidney	Well-differentiated neuroendocrine tumor of left kidney
Benign neoplasm of left female breast	Benign neoplasm of left breast
Benign neoplasm of right female breast	Benign neoplasm of right breast
Infiltrating ductal carcinoma of central portion of left female breast	Infiltrating duct carcinoma of central portion of left breast
Infiltrating ductal carcinoma of central portion of right female breast	Infiltrating duct carcinoma of central portion of right breast
Infiltrating ductal carcinoma of lower inner quadrant of left female breast	Infiltrating duct carcinoma of lower inner quadrant of left breast
Infiltrating ductal carcinoma of lower inner quadrant of right female breast	Infiltrating duct carcinoma of lower inner quadrant of right breast
Infiltrating ductal carcinoma of lower outer quadrant of left female breast	Infiltrating duct carcinoma of lower outer quadrant of left breast
Infiltrating ductal carcinoma of lower outer quadrant of right female breast	Infiltrating duct carcinoma of lower outer quadrant of right breast

Infiltrating ductal carcinoma of upper inner quadrant of left female breast	Infiltrating duct carcinoma of upper inner quadrant of left breast
Infiltrating ductal carcinoma of upper inner quadrant of right female breast	Infiltrating duct carcinoma of upper inner quadrant of right breast
Infiltrating ductal carcinoma of upper outer quadrant of left female breast	Infiltrating duct carcinoma of upper outer quadrant of left breast
Infiltrating ductal carcinoma of upper outer quadrant of right female breast	Infiltrating duct carcinoma of upper outer quadrant of right breast
Infiltrating lobular carcinoma of right female breast	Lobular carcinoma of right breast
Primary malignant neoplasm of bilateral female breasts	Primary malignant neoplasm of bilateral breasts
Recurrent primary malignant neoplasm of left female breast	Recurrent primary malignant neoplasm of left breast
Recurrent primary malignant neoplasm of right female breast	Recurrent primary malignant neoplasm of right breast

## Additions

The following problem to ICD-10-CM mappings will be available in the Clinical Profile, Problems area of iKnowMed. The ICD-10-CM codes you see below are new as of Tuesday, Oct. 1, 2024.

Problem	ICD-10 Codes
Adverse reaction to drug	<ul style="list-style-type: none"> <li>T45.AX5A Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter</li> <li>T45.AX5D Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter</li> <li>T45.AX5S Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela</li> </ul>
Aftercare	Z51.A Encounter for sepsis aftercare
Anal fistula	<ul style="list-style-type: none"> <li>K60.30 Anal fistula, unspecified</li> <li>K60.311 Anal fistula, simple, initial</li> <li>K60.312 Anal fistula, simple, persistent</li> <li>K60.313 Anal fistula, simple, recurrent</li> <li>K60.319 Anal fistula, simple, unspecified</li> <li>K60.321 Anal fistula, complex, initial</li> <li>K60.322 Anal fistula, complex, persistent</li> <li>K60.323 Anal fistula, complex, recurrent</li> <li>K60.329 Anal fistula, complex, unspecified</li> </ul>
Anaplastic large cell lymphoma, ALK negative	C84.7B Anaplastic large cell lymphoma, ALK-negative, in remission

Problem	ICD-10 Codes
Anaplastic lymphoma kinase positive anaplastic large cell lymphoma	C84.6A Anaplastic large cell lymphoma, ALK-positive, in remission
Angioimmunoblastic T-cell lymphoma	<ul style="list-style-type: none"> <li>• C86.41 Blastic NK-cell lymphoma, in remission</li> <li>• C86.50 Angioimmunoblastic T-cell lymphoma not having achieved remission</li> <li>• C86.51 Angioimmunoblastic T-cell lymphoma, in remission</li> </ul>
Anorectal fistula	<ul style="list-style-type: none"> <li>• K60.50 Anorectal fistula, unspecified</li> <li>• K60.511 Anorectal fistula, simple, initial</li> <li>• K60.512 Anorectal fistula, simple, persistent</li> <li>• K60.513 Anorectal fistula, simple, recurrent</li> <li>• K60.519 Anorectal fistula, simple, unspecified</li> <li>• K60.521 Anorectal fistula, complex, initial</li> <li>• K60.522 Anorectal fistula, complex, persistent</li> <li>• K60.523 Anorectal fistula, complex, recurrent</li> <li>• K60.529 Anorectal fistula, complex, unspecified</li> </ul>
Anosognosia	R41.85 Anosognosia
B-cell lymphoma	C85.1A Unspecified B-cell lymphoma, in remission
Bicuspid aortic valve	Q23.81 Bicuspid aortic valve
Blastic plasmacytoid dendritic cell neoplasm	C86.40 Blastic NK-cell lymphoma not having achieved remission
Burkitt's lymphoma (clinical)	C83.7A Burkitt lymphoma, in remission
Carcinoid heart disease	E34.01 Carcinoid heart syndrome
Carcinoid syndrome	<ul style="list-style-type: none"> <li>• E34.00 Carcinoid syndrome, unspecified</li> <li>• E34.09 Other carcinoid syndrome</li> </ul>
Central centrifugal cicatricial alopecia	L66.81 Central centrifugal cicatricial alopecia
Childhood obesity	<ul style="list-style-type: none"> <li>• Z68.55 Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age</li> <li>• Z68.56 Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age</li> </ul>

Problem	ICD-10 Codes
Cholestatic pruritus	L29.81, Cholestatic pruritus
Cleft leaflet of mitral valve	Q23.82 Congenital mitral valve cleft leaflet
<ul style="list-style-type: none"> <li>• Congenital anomaly of aortic valve</li> <li>• Congenital anomaly of mitral valve</li> </ul>	Q23.88 Other congenital malformations of aortic and mitral valves
Degeneration of lumbar intervertebral disc	<ul style="list-style-type: none"> <li>• M51.360 Other intervertebral disc degeneration, lumbar region with discogenic back pain only</li> <li>• M51.361 Other intervertebral disc degeneration, lumbar region with lower extremity pain only</li> <li>• M51.362 Other intervertebral disc degeneration, lumbar region with discogenic back pain and lower extremity pain</li> <li>• M51.369 Other intervertebral disc degeneration, lumbar region without mention of lumbar back pain or lower extremity pain</li> </ul>
Degeneration of lumbosacral intervertebral disc	<ul style="list-style-type: none"> <li>• M51.370 Other intervertebral disc degeneration, lumbosacral region with discogenic back pain only</li> <li>• M51.371 Other intervertebral disc degeneration, lumbosacral region with lower extremity pain only</li> <li>• M51.372 Other intervertebral disc degeneration, lumbosacral region with discogenic back pain and lower extremity pain</li> <li>• M51.379 Other intervertebral disc degeneration, lumbosacral region without mention of lumbar back pain or lower extremity pain</li> </ul>
Dehiscence of surgical wound	<ul style="list-style-type: none"> <li>• T81.321A Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, initial encounter</li> <li>• T81.321D Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, subsequent encounter</li> <li>• T81.321S Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, sequela</li> <li>• T81.328A Disruption or dehiscence of closure of other specified internal operation (surgical) wound, initial encounter</li> <li>• T81.328D Disruption or dehiscence of closure of other specified internal operation (surgical) wound, subsequent encounter</li> <li>• T81.328S Disruption or dehiscence of closure of other specified internal operation (surgical) wound, sequela</li> <li>• T81.329A Deep disruption or dehiscence of operation wound, unspecified, initial encounter</li> </ul>

Problem	ICD-10 Codes
	<ul style="list-style-type: none"> <li>T81.329D Deep disruption or dehiscence of operation wound, unspecified, subsequent encounter</li> <li>T81.329S Deep disruption or dehiscence of operation wound, unspecified, sequela</li> </ul>
Diffuse follicle center lymphoma	C82.5A Diffuse follicle center lymphoma, in remission
Diffuse large B-cell lymphoma	<ul style="list-style-type: none"> <li>C83.398 Diffuse large B-cell lymphoma of other extranodal and solid organ sites</li> <li>C83.3A Diffuse large B-cell lymphoma, in remission</li> </ul>
Diffuse non-Hodgkin's lymphoma	<ul style="list-style-type: none"> <li>C83.8A Other non-follicular lymphoma, in remission</li> <li>C83.9A Non-follicular (diffuse) lymphoma, unspecified, in remission</li> </ul>
Disorder of carbohydrate metabolism	E74.829 Other disorders of citrate metabolism
Disorder of carbohydrate transport	E74.820 SLC13A5 Citrate Transporter Disorder
Disorder of skeletal muscle	M62.85 Dysfunction of the multifidus muscles, lumbar region
Edema	<ul style="list-style-type: none"> <li>R60.0 - Localized edema</li> <li>R60.1 - Generalized edema</li> <li>R60.9 - Edema, unspecified</li> </ul>
Enteropathy-associated T-cell lymphoma	C86.20 Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission
Enteropathy-type (intestinal) T-cell	C86.21 Enteropathy-type (intestinal) T-cell lymphoma, in remission
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)	<ul style="list-style-type: none"> <li>C88.40 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission</li> <li>C88.41 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remission</li> </ul>
Extranodal NK/T-cell lymphoma, nasal type	<ul style="list-style-type: none"> <li>C85.9A Non-Hodgkin lymphoma, unspecified, in remission</li> <li>C86.00 Extranodal NK/T-cell lymphoma, nasal type not having achieved remission</li> <li>C86.01 Extranodal NK/T-cell lymphoma, nasal type, in remission</li> </ul>
Family history of familial multiple	Z83.72 Family history of familial adenomatous polyposis

Problem	ICD-10 Codes
Fanconi's anemia	D61.03 Fanconi anemia
Finding of receipt of benefit status	Z59.72 Insufficient welfare support
Finding related to health insurance issues	Z59.71 Insufficient health insurance coverage
Follicular lymphoma	<ul style="list-style-type: none"> <li>• C82.8A Other types of follicular lymphoma, in remission</li> <li>• C82.9A Follicular lymphoma, unspecified, in remission</li> </ul>
Follicular lymphoma grade 3a	C82.3A Follicular lymphoma grade IIIa, in remission
Follicular lymphoma grade 3b	C82.4A Follicular lymphoma grade IIIb, in remission
Follicular non-Hodgkin's lymphoma, large cell	C82.2A, Follicular lymphoma grade III, unspecified, in remission
Follicular non-Hodgkin's lymphoma, mixed small, cleaved cell and large cell (disorder)	C82.1A Follicular lymphoma grade II, in remission
Follicular non-Hodgkin's lymphoma, small, cleaved cell (clinical)	C82.0A Follicular lymphoma grade I, in remission
Frontal fibrosing alopecia	L66.12 Frontal fibrosing alopecia
Fy(a-b-) phenotype	Z67.A1 Duffy null
Fy(a-b+) phenotype	Z67.A3 Duffy b positive
Fy(a+b-) phenotype	Z67.A2 Duffy a positive
Fy(a+b+) phenotype	Z67.A4 Duffy a and b positive
Gastrointestinal anastomotic dehiscence	<ul style="list-style-type: none"> <li>• T81.320A Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, initial encounter</li> <li>• T81.320D Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, subsequent encounter</li> <li>• T81.320S Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, sequela</li> </ul>
Genetic susceptibility to genetic disorder	<ul style="list-style-type: none"> <li>• Z15.1 Genetic susceptibility to epilepsy and neurodevelopmental disorders</li> <li>• Z15.2 Genetic susceptibility to obesity</li> </ul>
Heavy chain disease	<ul style="list-style-type: none"> <li>• C88.20 Heavy chain disease not having achieved remission</li> <li>• C88.21 Heavy chain disease, in remission</li> </ul>

Problem	ICD-10 Codes
Hepatosplenic T-cell lymphoma	<ul style="list-style-type: none"> <li>• C86.10 Hepatosplenic T-cell lymphoma not having achieved remission</li> <li>• C86.11 Hepatosplenic T-cell lymphoma, in remission</li> </ul>
History of adenomatous polyp of colon	<ul style="list-style-type: none"> <li>• Z86.0101 Personal history of adenomatous and serrated colon polyps</li> <li>• Z86.0102 Personal history of hyperplastic colon polyps</li> </ul>
History of drug therapy	<ul style="list-style-type: none"> <li>• Z92.26 Personal history of immune checkpoint inhibitor therapy</li> </ul>
History of polyp of colon	<ul style="list-style-type: none"> <li>• Z86.0100 Personal history of colon polyps, unspecified</li> <li>• Z86.0109, Personal history of other colon polyps</li> </ul>
Hodgkin lymphoma lymphocytic depletion	C81.3A Lymphocyte depleted Hodgkin lymphoma, in remission
Hodgkin's disease in remission	<ul style="list-style-type: none"> <li>• C81.7A Other Hodgkin lymphoma, in remission</li> <li>• C81.9A Hodgkin lymphoma, unspecified, in remission</li> </ul>
Hodgkin's disease, nodular sclerosis	<ul style="list-style-type: none"> <li>• C81.0A Nodular lymphocyte predominant Hodgkin lymphoma, in remission</li> <li>• C81.1A Nodular sclerosis Hodgkin lymphoma, in remission</li> </ul>
Hormone receptor negative neoplasm	<ul style="list-style-type: none"> <li>• Z17.420 Hormone receptor negative with human epidermal growth factor receptor 2 positive status</li> <li>• Z17.421 Hormone receptor negative with human epidermal growth factor receptor 2 negative status</li> </ul>
Hormone receptor positive tumor	<ul style="list-style-type: none"> <li>• Z17.410 Hormone receptor positive with human epidermal growth factor receptor 2 positive status</li> <li>• Z17.411 Hormone receptor positive with human epidermal growth factor receptor 2 negative status</li> </ul>
Human epidermal growth factor 2 gene amplification not detected	Z17.32 Human epidermal growth factor receptor 2 negative status
Human epidermal growth factor receptor 2 gene amplification detected	Z17.31 Human epidermal growth factor receptor 2 positive status
Hypoglycemia	<ul style="list-style-type: none"> <li>• E16.A1 Hypoglycemia level 1</li> <li>• E16.A2 Hypoglycemia level 2</li> <li>• E16.A3 Hypoglycemia level 3</li> </ul>
Immunoproliferative small intestinal disease (clinical)	<ul style="list-style-type: none"> <li>• C88.30 Immunoproliferative small intestinal disease not having achieved remission</li> <li>• C88.31 Immunoproliferative small intestinal disease, in remission</li> </ul>

Problem	ICD-10 Codes
Intentional poisoning by drug	<ul style="list-style-type: none"> <li>• T45.AX3A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, initial encounter</li> <li>• T45.AX3D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, subsequent encounter</li> <li>• T45.AX3S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, sequela</li> </ul>
Intentional self-poisoning	<ul style="list-style-type: none"> <li>• T45.AX2A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, initial encounter</li> <li>• T45.AX2D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, subsequent encounter</li> <li>• T45.AX2S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, sequela</li> </ul>
Itching of skin	L29.89 Other pruritus
Kleefstra syndrome	Q87.86 Kleefstra syndrome
Lichen planopilaris	<ul style="list-style-type: none"> <li>• L66.10 Lichen planopilaris, unspecified</li> <li>• L66.11 Classic lichen planopilaris</li> <li>• L66.19 Other lichen planopilaris</li> </ul>
Lymphocyte-rich classical Hodgkin lymphoma	C81.4A Lymphocyte-rich Hodgkin lymphoma, in remission
Malignant immunoproliferative disease (clinical)	<ul style="list-style-type: none"> <li>• C88.80 Other malignant immunoproliferative diseases not having achieved remission</li> <li>• C88.81 Other malignant immunoproliferative diseases, in remission</li> <li>• C88.90 Malignant immunoproliferative disease, unspecified not having achieved remission</li> <li>• C88.91 Malignant immunoproliferative disease, unspecified, in remission</li> </ul>
Malignant lymphoma - small lymphocytic	C83.0A Small cell B-cell lymphoma, in remission
Mantle cell lymphoma	C83.1A Mantle cell lymphoma, in remission
Mature T-cell AND/OR NK cell neoplasm	<ul style="list-style-type: none"> <li>• C84.9A Mature T/NK-cell lymphomas, unspecified, in remission</li> <li>• C84.ZA Other mature T/NK-cell lymphomas, in remission</li> </ul>

Problem	ICD-10 Codes
Mixed cellularity Hodgkins lymphoma	C81.2A Mixed cellularity Hodgkin lymphoma, in remission
Mycosis fungoides (clinical)	C84.0A Mycosis fungoides, in remission
Non-Hodgkin's lymphoma in remission	C85.8A Other specified types of non-Hodgkin lymphoma, in remission
Obese class I	E66.811 Obesity, class 1
Obesity	E66.89 Other obesity not elsewhere classified
Obesity, class II	E66.812 Obesity, class 2
Obesity, class III	E66.813 Obesity, class 3
Peripheral T-cell lymphoma (clinical)	C84.4A Peripheral T-cell lymphoma, not elsewhere classified, in remission
Poisoning by drug AND/OR medicinal substance	<ul style="list-style-type: none"> <li>• T45.AX1A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), initial encounter</li> <li>• T45.AX1D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), subsequent encounter</li> <li>• T45.AX1S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequela</li> <li>• T45.AX4A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, initial encounter</li> <li>• T45.AX4D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter</li> <li>• T45.AX4S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, sequela</li> </ul>
Precursor cell lymphoblastic lymphoma	C83.5A Lymphoblastic (diffuse) lymphoma, in remission
Presymptomatic type 1 diabetes mellitus	<ul style="list-style-type: none"> <li>• E10.A0 Type 1 diabetes mellitus, presymptomatic, unspecified</li> <li>• E10.A1 Type 1 diabetes mellitus, presymptomatic, Stage 1</li> <li>• E10.A2 Type 1 diabetes mellitus, presymptomatic, Stage 2</li> </ul>

Problem	ICD-10 Codes
Primary central nervous system lymphoma	<ul style="list-style-type: none"> <li>C83.390 Primary central nervous system lymphoma</li> </ul>
Primary cutaneous CD30+ large T-cell lymphoma	<ul style="list-style-type: none"> <li>C86.60 Primary cutaneous CD30-positive T-cell proliferations not having achieved remission</li> <li>C86.61 Primary cutaneous CD30-positive T-cell proliferations, in remission</li> </ul>
Primary cutaneous follicular center B-cell lymphoma	C82.6A Cutaneous follicle center lymphoma, in remission
Primary cutaneous T-cell lymphoma	C84.AA Cutaneous T-cell lymphoma, unspecified, in remission
Primary mediastinal (thymic) large B-cell lymphoma	C85.2A Mediastinal (thymic) large B-cell lymphoma, in remission
Progesterone receptor negative neoplasm	Z17.22 Progesterone receptor negative status
Progesterone receptor positive tumor	Z17.21 Progesterone receptor positive status
Pulmonary embolism	<ul style="list-style-type: none"> <li>I26.03 Cement embolism of pulmonary artery with acute cor pulmonale</li> <li>I26.95 Cement embolism of pulmonary artery without acute cor pulmonale</li> </ul>
Pulmonary fat embolism	<ul style="list-style-type: none"> <li>I26.04 Fat embolism of pulmonary artery with acute cor pulmonale</li> <li>I26.96 Fat embolism of pulmonary artery without acute cor pulmonale</li> </ul>
Rectal fistula	<ul style="list-style-type: none"> <li>K60.40 Rectal fistula, unspecified</li> <li>K60.411 Rectal fistula, simple, initial</li> <li>K60.412 Rectal fistula, simple, persistent</li> <li>K60.413 Rectal fistula, simple, recurrent</li> <li>K60.419 Rectal fistula, simple, unspecified</li> <li>K60.421 Rectal fistula, complex, initial</li> <li>K60.422 Rectal fistula, complex, persistent</li> <li>K60.423 Rectal fistula, complex, recurrent</li> <li>K60.429 Rectal fistula, complex, unspecified</li> </ul>
Scarring alopecia	L66.89 Other cicatricial alopecia
Sezary's disease	C84.1A Sezary disease, in remission
Stenosis of nasal valve	<ul style="list-style-type: none"> <li>J34.8200 Internal nasal valve collapse, unspecified</li> <li>J34.8201 Internal nasal valve collapse, static</li> <li>J34.8202 Internal nasal valve collapse, dynamic</li> <li>J34.8210 External nasal valve collapse, unspecified</li> <li>J34.8211 External nasal valve collapse, static</li> </ul>

Problem	ICD-10 Codes
	<ul style="list-style-type: none"> <li>• J34.8212 External nasal valve collapse, dynamic</li> <li>• J34.829 Nasal valve collapse, unspecified</li> </ul>
Subcutaneous panniculitis-like T-cell lymphoma	<ul style="list-style-type: none"> <li>• C86.30 Subcutaneous panniculitis-like T-cell lymphoma not having achieved remission</li> <li>• C86.31 Subcutaneous panniculitis-like T-cell lymphoma, in remission</li> </ul>
Synovitis and tenosynovitis	<ul style="list-style-type: none"> <li>• M65.90 Unspecified synovitis and tenosynovitis, unspecified site</li> <li>• M65.921 Unspecified synovitis and tenosynovitis, right upper arm</li> <li>• M65.922 Unspecified synovitis and tenosynovitis, left upper arm</li> <li>• M65.929 Unspecified synovitis and tenosynovitis, unspecified upper arm</li> <li>• M65.931 Unspecified synovitis and tenosynovitis, right forearm</li> <li>• M65.932 Unspecified synovitis and tenosynovitis, left forearm</li> <li>• M65.939 Unspecified synovitis and tenosynovitis, unspecified forearm</li> <li>• M65.951 Unspecified synovitis and tenosynovitis, right thigh</li> <li>• M65.952 Unspecified synovitis and tenosynovitis, left thigh</li> <li>• M65.959 Unspecified synovitis and tenosynovitis, unspecified thigh</li> <li>• M65.961 Unspecified synovitis and tenosynovitis, right lower leg</li> <li>• M65.962 Unspecified synovitis and tenosynovitis, left lower leg</li> <li>• M65.969 Unspecified synovitis and tenosynovitis, unspecified lower leg</li> <li>• M65.98 Unspecified synovitis and tenosynovitis, other site</li> </ul>
Synovitis and tenosynovitis of joint of hand	<ul style="list-style-type: none"> <li>• M65.941 Unspecified synovitis and tenosynovitis, right hand</li> <li>• M65.942 Unspecified synovitis and tenosynovitis, left hand</li> <li>• M65.949 Unspecified synovitis and tenosynovitis, unspecified hand</li> </ul>
Synovitis and tenosynovitis of multiple joints	M65.99 Unspecified synovitis and tenosynovitis, multiple sites
<ul style="list-style-type: none"> <li>• Synovitis of left ankle joint</li> <li>• Synovitis of joint of left foot</li> <li>• Tenosynovitis of left ankle</li> </ul>	M65.972 Unspecified synovitis and tenosynovitis, left ankle and foot

Problem	ICD-10 Codes
<ul style="list-style-type: none"> <li>Tenosynovitis of left foot</li> </ul>	
<ul style="list-style-type: none"> <li>Synovitis of right ankle joint</li> <li>Synovitis of joint of right foot</li> <li>Tenosynovitis of right ankle</li> <li>Tenosynovitis of right foot</li> </ul>	M65.971 Unspecified synovitis and tenosynovitis, right ankle and foot
Synovitis/tenosynovitis - shoulder	<ul style="list-style-type: none"> <li>M65.911 Unspecified synovitis and tenosynovitis, right shoulder</li> <li>M65.912 Unspecified synovitis and tenosynovitis, left shoulder</li> <li>M65.919 Unspecified synovitis and tenosynovitis, unspecified shoulder</li> </ul>
<ul style="list-style-type: none"> <li>Tenosynovitis of ankle</li> <li>Tenosynovitis of foot</li> <li>Synovitis of ankle joint</li> <li>Synovitis of joint of foot</li> </ul>	M65.979 Unspecified synovitis and tenosynovitis, unspecified ankle and foot
Uses less medication than prescribed	<ul style="list-style-type: none"> <li>T45.AX6A Underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter</li> <li>T45.AX6D Underdosing of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter</li> <li>T45.AX6S Underdosing of immune checkpoint inhibitors and immunostimulant drugs, sequela</li> </ul>
Waldenström macroglobulinemia	<ul style="list-style-type: none"> <li>C88.00 Waldenström macroglobulinemia not having achieved remission</li> <li>C88.01 Waldenström macroglobulinemia, in remission</li> </ul>